Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CEL-SCI Corporation
CVM | US
4.07
USD-0.21
-4.91%
CVM | US
About CEL-SCI Corporation
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
10/04/2026
Close
4.07
Open
4.25
High
4.25
Low
4.01
CEL-SCI Corporation a clinical-stage biotechnology company engages in the research development and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine a Leukocyte Interleukin injection which has completed a pivotal Phase 3 clinical trial for patients who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology a patented T-cell modulation process that stimulates the human immune system to fight bacterial viral parasitic infections autoimmune conditions allergies transplantation rejections and cancer. In addition the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna Virginia.
View LessCVM | US
Risk
102.5
Sharpe
-0.25
Luna's Score
34/100
Recommendation
Sell
Luna says (CVM | US)
What's Working
Low Market Beta (-0.4 to 0.8)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
145.6%1 month
102.5%3 months
99.2%6 months
95.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
6.78
Debt to equity
1.43
Debt to assets
0.50
Ent. to EBITDA
-3.71
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-25.52M
MarketCap
259.61M
MarketCap(USD)
259.61M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-62.70
Ret. on equity
-250.20
Short ratio
12.14
Short perc.
7.16
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.71
Range1M
1.71
Range3M
3.73
Volumes: Market Activity
Rel. volume
0.53
Price X volume
87.44K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.71 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.78 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 99.21 | - | Riskier |
| Debt to Equity | 1.43 | -1.23 | Expensive |
| Debt to Assets | 0.50 | 0.25 | Expensive |
| Market Cap | 259.61M | - | Emerging |
